Overview

• US precision oncology firm's Q1 net loss widened to $18 mln, EPS at -0.34

• Company's R&D and G&A expenses declined yr/yr due to lower research and personnel costs

Outlook

• Company expects cash runway to end of Q2 2027

Result Drivers

• R&D expenses were $15.3 million for the quarter ended March 31, 2026, compared to $17.4 million for the quarter ended March 31, 2025

• General and administrative expenses were $3.7 million for the quarter ended March 31, 2026, compared to $4.1 million for the quarter ended March 31, 2025

Company press release: ID:nGNX9XVwRX

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 EPS		-$0.34
Q1 Net Income		-$18.04 mln
Q1 Operating Expenses		$19.02 mln
Q1 Operating Income		-$19.02 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for PMV Pharmaceuticals Inc is $4.50, about 223.7% above its May 11 closing price of $1.39

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.